<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958930</url>
  </required_header>
  <id_info>
    <org_study_id>NeuroEM-001</org_study_id>
    <secondary_id>EM 1000-1</secondary_id>
    <nct_id>NCT02958930</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety and Efficacy of Transcranial Electromagnetic Treatment (TEMT) for the Treatment of Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroEM Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Byrd Alzheimer's Institute, University of South Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Diagnostic Institute, Tampa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NeuroEM Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and initial efficacy of Transcranial
      Electromagnetic Treatment (TEMT) in patients with mild/moderate Alzheimer's Disease.
      Throughout a 2-month treatment period, patients will be evaluated for cognitive performance,
      brain energy utilization, functional brain imaging, and blood/cerebrospinal fluid (CSF)
      markers for Alzheimer's Disease. Since all patients will receive TEMT, each patient's
      baseline measurements will serve as their own control for any treatment effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is currently no effective therapeutic to stabilize or reverse the cognitive impairment
      of Alzheimer's Disease (AD) and related dementias. Clinical trials with drugs have been
      unsuccessful because the wrong therapeutic target/species were selected, because drugs have
      great difficulty traversing the blood-brain barrier and getting into neurons, and/or because
      drugs largely have only a single mechanism of action. Since ever-increasing experimental
      evidence indicates that the toxic forms of both beta-amyloid and tau are the soluble
      &quot;oligomeric&quot; species of these two proteins, therapeutics to disaggregate these oligomers
      within neurons represent perhaps the best chance for attaining cognitive benefit in AD
      patients.

      Pre-clinical studies performed by the Sponsor and his collaborators have demonstrated that AD
      transgenic mice treated daily with electromagnetic waves in the radiofrequency (RF) range are
      protected from cognitive impairment or show a reversal of pre-existing cognitive impairment.
      These cognitive benefits appear to be due primarily to two complimentary mechanisms: 1)
      disaggregation of toxic protein oligomers within neurons, and 2) mitochondrial enhancement to
      increase energy metabolism. Moreover, no deleterious effects of treatment over many months
      have been observed in these pre-clinical studies.

      In order to provide similar treatment to mild/moderate Alzheimer's patients clinically,
      NeuroEM Therapeutics has developed a unique head device that provides electromagnetic (RF)
      treatment to the entire human forebrain at levels similar to those that provided cognitive
      benefits in pre-clinical studies. Using the MemorEM 1000 head device in the present Phase I
      trial, AD patients receive twice daily 1-hour treatments in-home, as administered by their
      caregiver. The device allows for the patient to have complete mobility for moving throughout
      their home.

      A comprehensive array of markers will be analyzed both during and following the 2-month
      treatment period, with baseline (pre-treatment) values serving as controls. Cognitive safety
      and efficacy will be evaluated using a variety of cognitive assessments including ADAS-cog
      (Primary), and secondary cognitive measures including ADCS-ADL, Rey AVLT, Trails A &amp; B, Digit
      span, and clock draw tasks. Treatment effects on brain energy metabolism will be determine by
      FDG-PET scans, while treatment effects on brain functional connectivity will be determined
      through both resting state MRI and Diffusion Tensor Imaging. Also being assessed are the
      effects of treatment on various beta-amyloid and tau protein species (e.g., monomers,
      oligomers) in both blood and CSF. Safety of the treatment will be monitored by regular
      Adverse Events Assessment, physiologic monitoring, and patient daily diaries maintained by
      the caregiver.

      Expected Results: The investigators expect that 2-months of daily electromagnetic (RF)
      treatment will not present any significant side effects or safety issues. The investigators
      further expect that cognitive measures will be stable and/or improve by the end of treatment.
      In addition, the investigators anticipate that brain functional connectivity may be improved
      and that enhanced brain metabolism (FDG-PET) will occur. Changes in blood/CSF levels of
      various beta-amyloid and tau species are also anticipated.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-Cog</measure>
    <time_frame>Change from baseline ADAS-Cog at 2 months</time_frame>
    <description>ADAS-Cog is the standard/benchmark test of cognitive performance evaluated in Alzheimer's-related clinical trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FDG-PET</measure>
    <time_frame>Change from baseline FDG-PET at 2 months</time_frame>
    <description>FDG-PET scanning is used to determine brain energy metabolism/utilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting state fMRI</measure>
    <time_frame>Change from baseline rsfMRI at 2 months</time_frame>
    <description>rsfMRI is an MRI scan used to evaluate brain functional connectivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion Tensor Imaging (DTI)</measure>
    <time_frame>Change from baseline DTI at 2 months</time_frame>
    <description>DTI is an MRI scan used to evaluate brain functional connectivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Susceptibility-Weighted Imaging (SWI)</measure>
    <time_frame>Change from Baseline SWI at 2 months</time_frame>
    <description>SWI is an MRI scan used to determine any brain microhemorrhages or tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and CSF beta-amyloid levels</measure>
    <time_frame>Change from Baseline beta-amyloid levels at 2 months</time_frame>
    <description>Blood and CSF will be analyzed for the toxic protein beta-amyloid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and CSF tau levels</measure>
    <time_frame>Change from Baseline tau levels at 2 months</time_frame>
    <description>Blood and CSF will be analyzed for the toxic protein tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and CSF markers of immune function</measure>
    <time_frame>Change from Baseline pro- and anti-inflammatory cytokine levels at 2 months</time_frame>
    <description>Blood and CSF will be analyzed for pro- and anti-inflammatory cytokines (same measure units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood and CSF markers of oxidative stress</measure>
    <time_frame>Change from Baseline oxidative stress levels at 2 months</time_frame>
    <description>Blood and CSF will be analyzed for oxidative markers (same measure units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Assessment</measure>
    <time_frame>Change from Baseline Adverse Event Assessment at 2 months</time_frame>
    <description>AEA will be the primary safety outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADCS-ADL score</measure>
    <time_frame>Change from Baseline ADCS-ADL score at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMSE score</measure>
    <time_frame>Change from Baseline MMSE score at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Deterioration score</measure>
    <time_frame>Change from Baseline Global Deterioration score at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hachinski score</measure>
    <time_frame>Change from Baseline Hachinski score at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rey AVLT score</measure>
    <time_frame>Change from Baseline Rey AVLT score at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trails A &amp; B score</measure>
    <time_frame>Change from Baseline Trails A &amp; B scores at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit span score</measure>
    <time_frame>Change from Baseline Digit span score at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clock draw score</measure>
    <time_frame>Change from Baseline Clock draw score at 2 months</time_frame>
    <description>This is a secondary cognitive outcome to assess effects of treatment on cognition.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Alzheimer Disease, Late Onset</condition>
  <arm_group>
    <arm_group_label>TEMT Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MemorEM 1000</intervention_name>
    <description>The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.</description>
    <arm_group_label>TEMT Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to
             the National Institute of Neurological and Communicative Disorders and
             Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.

          -  MMSE score 16 to 26

          -  Physical clearance for study participation as evaluated by the clinician.

          -  Caregiver (spouse, family member, etc.) who agrees to and is capable of taking care
             and being responsible for the participation of the patient in the study (keeping a
             diary of health measures they collect on the patient at home, logging the patient's
             condition daily, and assuming responsibility for administering daily in-home
             treatment). Caregiver to have non-impaired mental abilities and normal motor skills,
             as determined by the investigators at screening. The definition of caregivers for this
             study is adults providing unpaid care to relatives or friends to help them take care
             of themselves in such activities as managing finances, shopping, preparing meals, and
             going to doctor appointments.

          -  Agreement to participate in approximately 10 weeks during the study.

          -  Normal to near-normal vision and hearing with correction as needed (e.g. corrective
             lenses, hearing aid).

          -  Fluent in English

          -  Minimum of 8th grade education

          -  Head circumference between 53 - 58 cm (to minimize variability in head antenna
             locations)

          -  If medicated for AD, then use of cholinesterase inhibitors and/or memantine for at
             least 3 months, on stable dose for at least 60 days prior to screening, and
             maintenance on that dose for the period of this study.

          -  All other non-AD medications must be stable for a period of 4 weeks prior to screening

        Exclusion Criteria:

          -  CDR Global Score of 0, 0.5 or 3

          -  Severe agitation

          -  Mental retardation

          -  Unstable medical condition

          -  Use of benzodiazepines or barbiturates 2 weeks prior to screening

          -  Participation in a clinical trial with any investigational agent within 6 months prior
             to study enrollment and no history of immunotherapy research participation

          -  History of Epileptic Seizures or Epilepsy

          -  Patients with major depression (not controlled with medication), bipolar disorder or
             psychotic disorders or any other neurological or psychiatric condition (whether now or
             in the past). The investigator will obtain this information from available patient
             medical records, history provided by the patient and caregiver, interview, and
             neurological exam.

          -  Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more
             than one year and or in remission less than 3 years) or severe sleep deprivation

          -  Patients with metal implants in the head, (i.e. cochlear implants, implanted brain
             stimulators, aneurysm clips) with the exception of metal implants in mouth

          -  Patients with vitamin B12 deficiency, abnormal thyroid function, or personal history
             of either any clinically defined medical disorder or any clinically defined
             neurological/psychiatric disorder (other than AD), including (but not limited to):,
             stroke, brain lesions, , cerebrovascular condition, other neurodegenerative disease,
             significant head trauma (loss of consciousness greater than half an hour, or related
             anterograde amnesia), multiple sclerosis; or personal history of previous neurosurgery
             or brain radiation

          -  Patients with any signs or symptoms of increased intracranial pressure, as determined
             in a neurological exam.

          -  Patients with demonstrated brain micro-hemorrhages at screening

          -  Patients with a score of 4 or higher on the Hachinski Test

          -  Patients with a score of 2 or less on the Global Deterioration Scale

          -  Patients with hypertension that is unresponsive to anti-hypertensive medications

          -  Patients with a history of migraine headaches occurring more than once a month

          -  Patients with a history of cancer within the last 3 years

          -  Patients chronically taking anticoagulants or anti-platelets (at discretion of
             Principal Investigator)

          -  Pregnant women and women who have the ability to become pregnant

          -  Patients with compressed hair thickness of more than 5mm (which could increase
             distance between head antennas and the scalp).

          -  Cardiac pacemakers

          -  Implanted medication pumps

          -  Intracardiac lines

          -  Significant heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>63 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Byrd Alzheimer's Institute, University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Byrd Alzheimer's Institute, University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.neuroem.com</url>
    <description>Website provides additional information regarding this technology</description>
  </link>
  <reference>
    <citation>Arendash GW. Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease. J Alzheimers Dis. 2016 May 30;53(3):753-71. doi: 10.3233/JAD-160165. Review.</citation>
    <PMID>27258417</PMID>
  </reference>
  <reference>
    <citation>Arendash GW. Transcranial electromagnetic treatment against Alzheimer's disease: why it has the potential to trump Alzheimer's disease drug development. J Alzheimers Dis. 2012;32(2):243-66. doi: 10.3233/JAD-2012-120943. Review.</citation>
    <PMID>22810103</PMID>
  </reference>
  <reference>
    <citation>Arendash GW, Mori T, Dorsey M, Gonzalez R, Tajiri N, Borlongan C. Electromagnetic treatment to old Alzheimer's mice reverses Î²-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit. PLoS One. 2012;7(4):e35751. doi: 10.1371/journal.pone.0035751. Epub 2012 Apr 25.</citation>
    <PMID>22558216</PMID>
  </reference>
  <reference>
    <citation>Dragicevic N, Bradshaw PC, Mamcarz M, Lin X, Wang L, Cao C, Arendash GW. Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit? Neuroscience. 2011 Jun 30;185:135-49. doi: 10.1016/j.neuroscience.2011.04.012. Epub 2011 Apr 13.</citation>
    <PMID>21514369</PMID>
  </reference>
  <reference>
    <citation>Arendash GW, Sanchez-Ramos J, Mori T, Mamcarz M, Lin X, Runfeldt M, Wang L, Zhang G, Sava V, Tan J, Cao C. Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. J Alzheimers Dis. 2010;19(1):191-210. doi: 10.3233/JAD-2010-1228.</citation>
    <PMID>20061638</PMID>
  </reference>
  <reference>
    <citation>Mori T, Arendash GW. Electromagnetic field treatment enhances neuronal activity: Linkage to cognitive benefit and therapeutic implications for Alzheimer's Disease. J Alzheimer's Dis and Parkinsonism 2011: Vol. 1:102, http://dx.doi.org/10.4172/2161-0460.1000102.</citation>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Late Onset Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not anticipated that IPD will be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

